000130263 001__ 130263
000130263 005__ 20240124152850.0
000130263 0247_ $$2doi$$a10.1089/bio.2012.0015
000130263 0248_ $$2sideral$$a92401
000130263 037__ $$aART-2012-92401
000130263 041__ $$aeng
000130263 100__ $$aSolanas, E
000130263 245__ $$aIncubation with dimethyl sulfoxide prior to cryopreservation improves functionality of thawed human primary hepatocytes
000130263 260__ $$c2012
000130263 5203_ $$aBackground: Efficient cryopreservation of human hepatocytes is essential for their use in cell therapy. This study investigated the effects of adding melatonin and/or dimethyl sulfoxide (DMSO) to pre-incubation and/or freezing solutions on the viability and function of thawed human hepatocytes.
Methods: Isolated human hepatocytes were pre-incubated for 90 min at 4°C in Williams' Medium E (WEM), WEM containing 5 mM melatonin dissolved in DMSO, or WEM containing the equivalent amount of DMSO (1%). The hepatocytes were frozen in University of Wisconsin solution (UW) and 10% DMSO, with or without 5 mM melatonin. After thawing, viability, plating efficiency, mitochondrial dehydrogenase activity (MTT), and albumin and urea production were analyzed.
Results: Viability and plating efficiency were not affected by melatonin or DMSO in pre-incubation media. Unexpectedly, hepatocytes pre-incubated with DMSO had significantly higher MTT (29.7% vs. control, p<0.01), albumin (82.8% vs. control, p<0.05), and urea amounts (26.2% vs. control, p=0.06) than those incubated only with WEM. Hepatocytes pre-incubated in media containing melatonin had amounts between those of cells incubated with DMSO or only with WEM (p<0.05 for MTT and p>0.05 for albumin and urea values). Also, the addition of melatonin to the freezing media did not significantly improve any of the studied parameters (p>0.05).
Discussion: Adding 1% DMSO to pre-incubation media prior to the cryopreservation of human hepatocytes preserves hepatocyte function after thawing. These findings could be considered in current hepatocyte cryopreservation protocols.
000130263 540__ $$9info:eu-repo/semantics/openAccess$$aAll rights reserved$$uhttp://www.europeana.eu/rights/rr-f/
000130263 590__ $$a1.5$$b2012
000130263 591__ $$aMEDICAL LABORATORY TECHNOLOGY$$b16 / 31 = 0.516$$c2012$$dQ3$$eT2
000130263 591__ $$aCELL BIOLOGY$$b157 / 183 = 0.858$$c2012$$dQ4$$eT3
000130263 655_4 $$ainfo:eu-repo/semantics/article$$vinfo:eu-repo/semantics/publishedVersion
000130263 700__ $$aSostres, C
000130263 700__ $$aSerrablo, A
000130263 700__ $$aGarcía-Gil, A
000130263 700__ $$aAranguren, F
000130263 700__ $$aJimenez, P
000130263 700__ $$0(orcid)0000-0002-7119-2244$$aSerrano, MT.$$uUniversidad de Zaragoza
000130263 7102_ $$11007$$2610$$aUniversidad de Zaragoza$$bDpto. Medicina, Psiqu. y Derm.$$cArea Medicina
000130263 773__ $$g10, 5 (2012), 446-53$$pBIOPRESERVATION AND BIOBANKING$$tBIOPRESERVATION AND BIOBANKING$$x1947-5535
000130263 8564_ $$s207062$$uhttps://zaguan.unizar.es/record/130263/files/texto_completo.pdf$$yVersión publicada
000130263 8564_ $$s2610603$$uhttps://zaguan.unizar.es/record/130263/files/texto_completo.jpg?subformat=icon$$xicon$$yVersión publicada
000130263 909CO $$ooai:zaguan.unizar.es:130263$$particulos$$pdriver
000130263 951__ $$a2024-01-24-14:57:54
000130263 980__ $$aARTICLE